Annual CFO
-$259.17 M
+$4.04 M+1.53%
December 31, 2023
Summary
- As of February 8, 2025, PACB annual cash flow from operations is -$259.17 million, with the most recent change of +$4.04 million (+1.53%) on December 31, 2023.
- During the last 3 years, PACB annual CFO has fallen by -$278.68 million (-1428.89%).
- PACB annual CFO is now -1428.89% below its all-time high of $19.50 million, reached on December 31, 2020.
Performance
PACB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$45.46 M
+$8.80 M+16.22%
September 30, 2024
Summary
- As of February 8, 2025, PACB quarterly cash flow from operations is -$45.46 million, with the most recent change of +$8.80 million (+16.22%) on September 30, 2024.
- Over the past year, PACB quarterly CFO has increased by +$8.80 million (+16.22%).
- PACB quarterly CFO is now -160.33% below its all-time high of $75.36 million, reached on March 31, 2020.
Performance
PACB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$232.97 M
+$19.72 M+7.80%
September 30, 2024
Summary
- As of February 8, 2025, PACB TTM cash flow from operations is -$232.97 million, with the most recent change of +$19.72 million (+7.80%) on September 30, 2024.
- Over the past year, PACB TTM CFO has increased by +$19.72 million (+7.80%).
- PACB TTM CFO is now -1141.71% below its all-time high of $22.36 million, reached on March 31, 2020.
Performance
PACB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PACB Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.5% | +16.2% | +7.8% |
| 3 y3 years | -1428.9% | -11.8% | -148.5% |
| 5 y5 years | -290.1% | -163.4% | -197.5% |
PACB Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -133.1% | +1.5% | -43.4% | +52.0% | -109.5% | +16.5% |
| 5 y | 5-year | -1428.9% | +1.5% | -160.3% | +52.0% | -1141.7% | +16.5% |
| alltime | all time | -1428.9% | +1.5% | -160.3% | +52.0% | -1141.7% | +16.5% |
Pacific Biosciences Of California Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$45.46 M(-16.2%) | -$232.97 M(-7.8%) |
| Jun 2024 | - | -$54.26 M(-28.3%) | -$252.69 M(+5.2%) |
| Mar 2024 | - | -$75.68 M(+31.5%) | -$240.16 M(-7.3%) |
| Dec 2023 | -$259.17 M(-1.5%) | -$57.56 M(-11.7%) | -$259.17 M(-1.1%) |
| Sep 2023 | - | -$65.18 M(+56.2%) | -$262.18 M(+0.8%) |
| Jun 2023 | - | -$41.74 M(-55.9%) | -$260.05 M(-6.7%) |
| Mar 2023 | - | -$94.69 M(+56.3%) | -$278.87 M(+6.0%) |
| Dec 2022 | -$263.21 M(+136.7%) | -$60.57 M(-3.9%) | -$263.21 M(+12.3%) |
| Sep 2022 | - | -$63.05 M(+4.1%) | -$234.35 M(+10.6%) |
| Jun 2022 | - | -$60.56 M(-23.4%) | -$211.96 M(+26.8%) |
| Mar 2022 | - | -$79.03 M(+149.2%) | -$167.10 M(+50.3%) |
| Dec 2021 | -$111.18 M(-670.1%) | -$31.71 M(-22.0%) | -$111.18 M(+18.6%) |
| Sep 2021 | - | -$40.66 M(+158.8%) | -$93.73 M(+32.2%) |
| Jun 2021 | - | -$15.71 M(-32.0%) | -$70.89 M(-10.2%) |
| Mar 2021 | - | -$23.10 M(+62.0%) | -$78.96 M(-504.9%) |
| Dec 2020 | $19.50 M(-124.9%) | -$14.26 M(-19.9%) | $19.50 M(+25.1%) |
| Sep 2020 | - | -$17.81 M(-25.1%) | $15.59 M(-3.4%) |
| Jun 2020 | - | -$23.79 M(-131.6%) | $16.13 M(-27.9%) |
| Mar 2020 | - | $75.36 M(-514.5%) | $22.36 M(-128.6%) |
| Dec 2019 | -$78.31 M(+17.9%) | -$18.18 M(+5.3%) | -$78.31 M(-1.0%) |
| Sep 2019 | - | -$17.26 M(-1.7%) | -$79.12 M(+4.1%) |
| Jun 2019 | - | -$17.56 M(-30.6%) | -$76.03 M(+4.2%) |
| Mar 2019 | - | -$25.31 M(+33.3%) | -$72.97 M(+9.8%) |
| Dec 2018 | -$66.43 M(-1.6%) | -$18.98 M(+33.9%) | -$66.43 M(-1.8%) |
| Sep 2018 | - | -$14.18 M(-2.2%) | -$67.64 M(-5.1%) |
| Jun 2018 | - | -$14.50 M(-22.8%) | -$71.31 M(+2.4%) |
| Mar 2018 | - | -$18.77 M(-7.1%) | -$69.62 M(+3.1%) |
| Dec 2017 | -$67.52 M(-0.6%) | -$20.20 M(+13.2%) | -$67.52 M(+12.1%) |
| Sep 2017 | - | -$17.84 M(+39.3%) | -$60.22 M(+3.4%) |
| Jun 2017 | - | -$12.81 M(-23.2%) | -$58.26 M(-9.4%) |
| Mar 2017 | - | -$16.67 M(+29.2%) | -$64.33 M(-5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$67.93 M(+41.8%) | -$12.90 M(-18.7%) | -$67.93 M(+21.9%) |
| Sep 2016 | - | -$15.88 M(-15.9%) | -$55.74 M(+0.2%) |
| Jun 2016 | - | -$18.89 M(-6.8%) | -$55.64 M(+25.7%) |
| Mar 2016 | - | -$20.27 M(+2738.5%) | -$44.24 M(-7.6%) |
| Dec 2015 | -$47.89 M(-7.0%) | -$714.00 K(-95.5%) | -$47.89 M(-23.4%) |
| Sep 2015 | - | -$15.77 M(+110.4%) | -$62.53 M(+18.0%) |
| Jun 2015 | - | -$7.49 M(-68.7%) | -$53.00 M(-10.4%) |
| Mar 2015 | - | -$23.91 M(+55.7%) | -$59.12 M(+14.9%) |
| Dec 2014 | -$51.47 M(+72.5%) | -$15.36 M(+146.3%) | -$51.47 M(+1.5%) |
| Sep 2014 | - | -$6.24 M(-54.2%) | -$50.69 M(+97.0%) |
| Jun 2014 | - | -$13.62 M(-16.2%) | -$25.73 M(-9.8%) |
| Mar 2014 | - | -$16.26 M(+11.5%) | -$28.51 M(-4.4%) |
| Dec 2013 | -$29.83 M(-61.2%) | -$14.57 M(-177.8%) | -$29.83 M(-10.9%) |
| Sep 2013 | - | $18.72 M(-214.1%) | -$33.48 M(-52.1%) |
| Jun 2013 | - | -$16.41 M(-6.6%) | -$69.85 M(-9.3%) |
| Mar 2013 | - | -$17.57 M(-3.6%) | -$77.06 M(+0.3%) |
| Dec 2012 | -$76.82 M(-25.4%) | -$18.22 M(+3.3%) | -$76.82 M(+4.7%) |
| Sep 2012 | - | -$17.65 M(-25.3%) | -$73.37 M(-7.8%) |
| Jun 2012 | - | -$23.61 M(+36.2%) | -$79.57 M(-8.4%) |
| Mar 2012 | - | -$17.34 M(+17.4%) | -$86.85 M(-15.7%) |
| Dec 2011 | -$102.97 M(-15.6%) | -$14.77 M(-38.1%) | -$102.97 M(-19.1%) |
| Sep 2011 | - | -$23.85 M(-22.8%) | -$127.25 M(-6.9%) |
| Jun 2011 | - | -$30.89 M(-7.7%) | -$136.75 M(+6.3%) |
| Mar 2011 | - | -$33.46 M(-14.3%) | -$128.62 M(+5.4%) |
| Dec 2010 | -$122.00 M(+63.0%) | -$39.05 M(+17.1%) | -$122.00 M(+47.1%) |
| Sep 2010 | - | -$33.35 M(+46.6%) | -$82.95 M(+67.3%) |
| Jun 2010 | - | -$22.76 M(-15.2%) | -$49.59 M(+84.8%) |
| Mar 2010 | - | -$26.84 M | -$26.84 M |
| Dec 2009 | -$74.84 M(+95.4%) | - | - |
| Dec 2008 | -$38.30 M(+128.9%) | - | - |
| Dec 2007 | -$16.73 M | - | - |
FAQ
- What is Pacific Biosciences of California annual cash flow from operations?
- What is the all time high annual CFO for Pacific Biosciences of California?
- What is Pacific Biosciences of California annual CFO year-on-year change?
- What is Pacific Biosciences of California quarterly cash flow from operations?
- What is the all time high quarterly CFO for Pacific Biosciences of California?
- What is Pacific Biosciences of California quarterly CFO year-on-year change?
- What is Pacific Biosciences of California TTM cash flow from operations?
- What is the all time high TTM CFO for Pacific Biosciences of California?
- What is Pacific Biosciences of California TTM CFO year-on-year change?
What is Pacific Biosciences of California annual cash flow from operations?
The current annual CFO of PACB is -$259.17 M
What is the all time high annual CFO for Pacific Biosciences of California?
Pacific Biosciences of California all-time high annual cash flow from operations is $19.50 M
What is Pacific Biosciences of California annual CFO year-on-year change?
Over the past year, PACB annual cash flow from operations has changed by +$4.04 M (+1.53%)
What is Pacific Biosciences of California quarterly cash flow from operations?
The current quarterly CFO of PACB is -$45.46 M
What is the all time high quarterly CFO for Pacific Biosciences of California?
Pacific Biosciences of California all-time high quarterly cash flow from operations is $75.36 M
What is Pacific Biosciences of California quarterly CFO year-on-year change?
Over the past year, PACB quarterly cash flow from operations has changed by +$8.80 M (+16.22%)
What is Pacific Biosciences of California TTM cash flow from operations?
The current TTM CFO of PACB is -$232.97 M
What is the all time high TTM CFO for Pacific Biosciences of California?
Pacific Biosciences of California all-time high TTM cash flow from operations is $22.36 M
What is Pacific Biosciences of California TTM CFO year-on-year change?
Over the past year, PACB TTM cash flow from operations has changed by +$19.72 M (+7.80%)